All three U.S. manufactures of insulin to testify before Congress next week
WASHINGTON, D.C. – U.S. Rep. Diana DeGette (D-CO), chair of the House oversight panel that’s investigating the skyrocketing cost of insulin, announced today that all three U.S. manufacturers of insulin will be appearing before Congress next week.
DeGette, who chairs the House Energy and Commerce Committee’s Oversight and Investigations panel, made the announcement at the conclusion of what was the first of two hearings that DeGette’s panel is holding in as many weeks to determine why the cost of insulin has skyrocketed in recent years, and what Congress can do to make it more affordable for the 7.5 million Americans who need it to survive.
“Next week, we are going to have much of the supply chain here,” DeGette said in wrapping up Tuesday’s hearing. “We are going to have all three manufacturers and we’re going to have the three largest PBMs.”
After the hearing, DeGette said she wants these companies to explain why the cost of insulin continues to rise and why lower-cost alternatives still are not available to patients.
“In response to our request, all three U.S. manufacturers of insulin will be testifying before our committee next week,” DeGette said Tuesday, immediately after the hearing. “We want to know why the cost of this life-saving drug has skyrocketed in recent years, and why they’re not offering more lower-cost alternatives to patients.”
There are only three U.S. drug makers that currently manufacture insulin, they are: Eli Lilly, Novo Nordisk and Sanofi. All three will be testifying before DeGette’s panel when it reconvenes on Wednesday, April 10.